|
1
|
Dong H, Zhu G, Tamada K and Chen L: B7-H1,
a third member of the B7 family, co-stimulates T-cell proliferation
and interleukin-10 secretion. Nat Med. 5:1365–1369. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dong H, Strome SE, Salomao DR, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nomi T, Sho M, Akahori T, et al: Clinical
significance and therapeutic potential of the programmed death-1
ligand/programmed death-1 pathway in human pancreatic cancer. Clin
Cancer Res. 13:2151–2157. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ohigashi Y, Sho M, Yamada Y, et al:
Clinical significance of programmed death-1 ligand-1 and programmed
death-1 ligand-2 expression in human esophageal cancer. Clin Cancer
Res. 11:2947–2953. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen XL, Cao XD, Kang AJ, Wang KM, Su BS
and Wang YL: In situ expression and significance of B7
costimulatory molecules within tissues of human gastric carcinoma.
World J Gastroenterol. 9:1370–1373. 2003.
|
|
6
|
Wintterle S, Schreiner B, Mitsdoerffer M,
et al: Expression of the B7-related molecule B7-H1 by glioma cells:
a potential mechanism of immune paralysis. Cancer Res.
63:7462–7467. 2003.PubMed/NCBI
|
|
7
|
Dong H and Chen L: B7-H1 pathway and its
role in the evasion of tumor immunity. J Mol Med. 81:281–287.
2003.PubMed/NCBI
|
|
8
|
Iwai Y, Ishida M, Tanaka Y, Okazaki T,
Honjo T and Minato N: Involvement of PD-L1 on tumor cells in the
escape from host immune system and tumor immunotherapy by PD-L1
blockade. Proc Natl Acad Sci USA. 99:12293–12297. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Flies DB, Sandler BJ, Sznol M and Chen L:
Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J
Biol Med. 84:409–421. 2011.PubMed/NCBI
|
|
10
|
Okudaira K, Hokari R, Tsuzuki Y, et al:
Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse
pancreatic cancer model. Int J Oncol. 35:741–749. 2009.PubMed/NCBI
|
|
11
|
Sznol M and Chen L: Antagonist antibodies
to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human
cancer. Clin Cancer Res. 19:1021–1034. 2013. View Article : Google Scholar
|
|
12
|
Ghebeh H, Tulbah A, Mohammed S, et al:
Expression of B7-H1 in breast cancer patients is strongly
associated with high proliferative Ki-67-expressing tumor cells.
Int J Cancer. 121:751–758. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tamura H, Ishibashi M, Yamashita T, et al:
Marrow stromal cells induce B7-H1 expression on myeloma cells,
generating aggressive characteristics in multiple myeloma.
Leukemia. 27:464–472. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cao Y, Zhang L, Kamimura Y, et al: B7-H1
overexpression regulates epithelial-mesenchymal transition and
accelerates carcinogenesis in skin. Cancer Res. 71:1235–1243. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Azuma T, Yao S, Zhu G, Flies AS, Flies SJ
and Chen L: B7-H1 is a ubiquitous antiapoptotic receptor on cancer
cells. Blood. 111:3635–3643. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang F, Ma J, Liu J, Jin H and Huang D:
Synthetic small peptides acting on B7H1 enhance apoptosis in
pancreatic cancer cells. Mol Med Rep. 6:553–557. 2012.PubMed/NCBI
|
|
17
|
Geng L, Huang D, Liu J, et al: B7-H1
up-regulated expression in human pancreatic carcinoma tissue
associates with tumor progression. J Cancer Res Clin Oncol.
134:1021–1027. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tsushima F, Yao S, Shin T, et al:
Interaction between B7-H1 and PD-1 determines initiation and
reversal of T-cell anergy. Blood. 110:180–185. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Goldberg MV, Maris CH, Hipkiss EL, et al:
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8
T cells. Blood. 110:186–192. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Okazaki T and Honjo T: The PD-1-PD-L
pathway in immunological tolerance. Trends Immunol. 27:195–201.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kondo A, Yamashita T, Tamura H, et al:
Interferon-γ and tumor necrosis factor-α induce an immunoinhibitory
molecule, B7-H1, via nuclear factor-κB activation in blasts in
myelodysplastic syndromes. Blood. 116:1124–1131. 2010.
|
|
22
|
Ghebeh H, Lehe C, Barhoush E, et al:
Doxorubicin downregulates cell surface B7-H1 expression and
upregulates its nuclear expression in breast cancer cells: role of
B7-H1 as an anti-apoptotic molecule. Breast Cancer Res. 12:R482010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Knudsen KE, Diehl JA, Haiman CA and
Knudsen ES: Cyclin D1: polymorphism, aberrant splicing and cancer
risk. Oncogene. 25:1620–1628. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brahmer JR, Drake CG, Wollner I, et al:
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in
refractory solid tumors: safety, clinical activity,
pharmacodynamics, and immunologic correlates. J Clin Oncol.
28:3167–3175. 2010. View Article : Google Scholar
|
|
25
|
Brahmer JR, Tykodi SS, Chow LQ, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Parsa AT, Waldron JS, Panner A, et al:
Loss of tumor suppressor PTEN function increases B7-H1 expression
and immunoresistance in glioma. Nat Med. 13:84–88. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takahashi R, Hirata Y, Sakitani K, et al:
Therapeutic effect of c-Jun N-terminal kinase inhibition on
pancreatic cancer. Cancer Sci. 104:337–344. 2013. View Article : Google Scholar : PubMed/NCBI
|
